PharmacyPress Release

Hansa Biopharma to host conference call to provide Year-End report 2020 and Business Update

Hansa Biopharma will publish its Year-End report 2020 at 8:00 CET on February 4, 2021. All interested parties are invited to participate

By PR Newswire

LUND, Sweden, Jan. 27, 2021  — Hansa Biopharma will publish its Year-End report 2020 at 8:00 CET on February 4, 2021. All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update, on the same date at 14:00 CET/2:00pm EST.

The event will be hosted by it’s CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.

Slides used in the presentation will be live on the company website during the call under “Events & Webcast,” and will also be made available online after the call. This was conveyed to Prittle Prattle News by a Press Release.

To participate in the telephone conference, please use the dial-in details provided below:

Sweden: +46 8 50 55 83 50

United Kingdom: +44 333 300 92 72

United States: +1 833 526 83 47

The webcast will be available on https://streams.eventcdn.net/hansa/2020h2/register

About:

Hansa Biopharma is leveraging its proprietary enzyme technology platform to enable immunomodulatory treatments for transplants, rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy and cancer.

The Company’s lead product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and tissue transplantation and acute autoimmune indications. The European Commission has conditionally approved Idefirix (imlifidase) for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor.

For further information, please contact:

Klaus Sindahl

Head of Investor Relations

Mobile: +46 (0) 709-298 269

E-mail: klaus.sindahl@hansabiopharma.com  

Katja Margell

Head of Corporate Communications 

Hansa Biopharma 

Mobile: +46 (0) 768-198 326

E-mail: katja.margell@hansabiopharma.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharma-to-host-conference-call-to-provide-year-end-report-2020-and-business-update,c3274551

The following files are available for download:

 

Related Posts

1 of 417